Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Read More…
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Phone805-562-0500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$358.11 million
Profitability
Miscellaneous
Employees1,099
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Inogen (NASDAQ:INGN) Frequently Asked Questions
What is Inogen's stock symbol?
Inogen trades on the NASDAQ under the ticker symbol "INGN."
How were Inogen's earnings last quarter?
Inogen Inc (NASDAQ:INGN) announced its quarterly earnings data on Wednesday, August, 7th. The medical technology company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by $0.05. The medical technology company earned $101.10 million during the quarter, compared to analyst estimates of $106.88 million. Inogen had a net margin of 11.24% and a return on equity of 13.34%. The firm's revenue for the quarter was up 3.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.65 earnings per share. View Inogen's Earnings History.
When is Inogen's next earnings date?
What guidance has Inogen issued on next quarter's earnings?
Inogen issued an update on its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $370-375 million, compared to the consensus revenue estimate of $408.89 million.
What price target have analysts set for INGN?
7 Wall Street analysts have issued twelve-month price objectives for Inogen's shares. Their forecasts range from $47.00 to $91.00. On average, they expect Inogen's share price to reach $67.60 in the next twelve months. This suggests a possible upside of 31.3% from the stock's current price. View Analyst Price Targets for Inogen.
What is the consensus analysts' recommendation for Inogen?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Inogen.
What are Wall Street analysts saying about Inogen stock?
Here are some recent quotes from research analysts about Inogen stock:
- 1. Needham & Company LLC analysts commented, "INGN beat consensus revenue and EPS in 4Q18 and management maintained its 2019 guidance for revenue and adjusted EBITDA. The revenue upside was driven by the DTC sales force expansion and was partially offset by slower domestic B2B sales as a single large customer slowed its orders. Gross margin was up Y/Y and beat our estimate while operating margin was down Y/Y and beat our estimate. INGN continues to see the benefit of its DTC sales force expansion as DTC sales grew 50% in 4Q18. We expect the ongoing sales force expansion, new product cycle, and the market shift to POCs to sustain strong growth and drive upside to consensus and we reiterate our Strong Buy rating." (2/27/2019)
- 2. According to Zacks Investment Research, "Inogen outperformed the industry in a year’s time. The company continues to gain from its strong portfolio of portable oxygen concentrators (POC) which has been lending it a competitive edge in the MedTech space. Solid business-to-business revenues also buoy optimism. These apart, the company’s direct-to-consumer unit performed exceedingly well in recent times. Moreover, management remains optimistic about its international revenues, which saw solid growth in Europe in recent times. The raised revenue guidance for 2018 is also an added positive. Inogen issued a bullish guidance for 2019 as well. On the flip side, Inogen’s rental revenues declined on a year-over-year basis in recent times. In fact, the company expects rental revenues to remain down in 2018 and grow modestly in 2019. Rising operating expenses are discouraging as well. In the LTOT market, POC adoption continues to face significant headwinds." (2/14/2019)
Has Inogen been receiving favorable news coverage?
Headlines about INGN stock have been trending somewhat positive recently, InfoTrie reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Inogen earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave media headlines about the medical technology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Inogen.
Are investors shorting Inogen?
Inogen saw a decline in short interest during the month of August. As of August 31st, there was short interest totalling 3,141,000 shares, a decline of 27.2% from the July 31st total of 4,314,500 shares. Based on an average daily trading volume, of 534,600 shares, the short-interest ratio is currently 5.9 days. Currently, 17.3% of the shares of the stock are sold short. View Inogen's Current Options Chain.
Who are some of Inogen's key competitors?
Some companies that are related to Inogen include Wright Medical Group (WMGI), Avanos Medical (AVNS), Establishment Labs (ESTA), Sientra (SIEN), Invacare (IVC), RTI Surgical (RTIX), ConforMIS (CFMS), Lakeland Industries (LAKE), Rewalk Robotics (RWLK), Histogenics (HSGX), Precision Therapeutics (POAI), COLLPLANT HOLDI/S (CLGN), Wound Management Technologies (WNDM), NanoVibronix (NAOV) and Bionik Laboratories (BNKL).
What other stocks do shareholders of Inogen own?
Who are Inogen's key executives?
Inogen's management team includes the folowing people:
- Mr. Scott Wilkinson, CEO, Pres & Director (Age 54)
- Mr. Brenton Taylor, Co-founder & Exec. VP of Engineering (Age 38)
- Ms. Alison Perry Bauerlein, Co-founder, Exec. VP of Fin., CFO, Corp. Sec. & Treasurer (Age 38)
- Mr. Bart Sanford, Exec. VP of Operations (Age 53)
- Mr. Byron Myers, Exec. VP of Sales & Marketing (Age 40)
Who are Inogen's major shareholders?
Inogen's stock is owned by many different of retail and institutional investors. Top institutional investors include Brown Capital Management LLC (16.63%), BlackRock Inc. (10.36%), Vanguard Group Inc. (7.76%), AQR Capital Management LLC (4.19%), Janus Henderson Group PLC (2.76%) and Janus Henderson Group PLC (2.76%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Institutional Ownership Trends for Inogen.
Which institutional investors are selling Inogen stock?
INGN stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Royal Bank of Canada, Morgan Stanley, Waddell & Reed Financial Inc., Kornitzer Capital Management Inc. KS, Chicago Capital LLC, Wells Fargo & Company MN and Price T Rowe Associates Inc. MD. Company insiders that have sold Inogen company stock in the last year include Brenton Taylor, Heath Lukatch, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson and Raymond Huggenberger. View Insider Buying and Selling for Inogen.
Which institutional investors are buying Inogen stock?
INGN stock was bought by a variety of institutional investors in the last quarter, including Brown Capital Management LLC, AQR Capital Management LLC, Riverbridge Partners LLC, Balyasny Asset Management LLC, Asymmetry Capital Management L.P., Canada Pension Plan Investment Board, Fort Washington Investment Advisors Inc. OH and Summit Creek Advisors LLC. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch and Loren L Mcfarland. View Insider Buying and Selling for Inogen.
How do I buy shares of Inogen?
Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Inogen's stock price today?
One share of INGN stock can currently be purchased for approximately $51.50.
How big of a company is Inogen?
Inogen has a market capitalization of $1.13 billion and generates $358.11 million in revenue each year. The medical technology company earns $51.85 million in net income (profit) each year or $2.30 on an earnings per share basis. Inogen employs 1,099 workers across the globe.View Additional Information About Inogen.
What is Inogen's official website?
How can I contact Inogen?
Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]
MarketBeat Community Rating for Inogen (NASDAQ INGN)
MarketBeat's community ratings are surveys of what our community members think about Inogen and other stocks. Vote "Outperform" if you believe INGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
